Skip to main content

Alpha Cognition Inc(ACOG-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.74
Day High5.99
Open:5.89
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Alpha Cognition Inc

Select a category then submit the form to load news
Motley Fool
Solas Capital Loads Up On Kyndryl With 407,000 Shares Bought
Tipranks
Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG) and Fulcrum Therapeutics (FULC)
Business Wire
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
Business Wire
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
Business Wire
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
Business Wire
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
Tipranks
Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)
Tipranks
Alpha Cognition’s Earnings Call: Strong Sales and Strategic Growth
Business Wire
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
Business Wire
Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
Tipranks
Alpha Cognition Inc. Raises $35 Million in Oversubscribed Public Offering
Tipranks
Alpha Cognition Inc. Announces Public Offering to Boost Alzheimer’s Treatment Launch
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Alpha Cognition Inc (ACOG) and Exelixis (EXEL)
TheNewswire.com
Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference
Business Wire
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
Business Wire
Alpha Cognition to Present Clinical Data at ASCP Annual Meeting
Business Wire
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
Business Wire
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
Business Wire
Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
Tipranks
Alpha Cognition Inc. Reports Strong Q2 2025 Results
Business Wire
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
Business Wire
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
Business Wire
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
Business Wire
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
Business Wire
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
Tipranks
Analysts’ Top Healthcare Picks: Sangamo Biosciences (SGMO), Alpha Cognition Inc (ACOG)
Business Wire
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
Business Wire
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
Newsfile
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Business Wire
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
Business Wire
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Business Wire
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

Profile

Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.